Candriam SCA’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-462,239
| Closed | -$79.5M | – | 905 |
|
|
2021
Q3 | $79.5M | Sell |
462,239
-94,816
| -17% | -$12.4M | 0.54% | 43 |
|
|
2021
Q2 | $69.9M | Buy |
557,055
+121
| +0% | +$15.3K | 0.48% | 46 |
|
|
2021
Q1 | $68.4M | Sell |
556,934
-1
| -0% | -$129 | 0.57% | 35 |
|
|
2020
Q4 | $71.3M | Buy |
556,935
+51,555
| +10% | +$6.04M | 0.56% | 35 |
|
|
2020
Q3 | $56.9M | Buy |
505,380
+124,371
| +33% | +$12.4M | 0.53% | 36 |
|
|
2020
Q2 | $36.3M | Sell |
381,009
-101,549
| -21% | -$9.79M | 0.38% | 59 |
|
|
2020
Q1 | $25M | Buy |
482,558
+28
| +0% | +$2.18K | 0.28% | 76 |
|
|
2019
Q4 | $25.6M | Sell |
482,530
-68,970
| -13% | -$3.14M | 0.27% | 76 |
|
|
2019
Q3 | $21.8M | Buy |
551,500
+169,552
| +44% | +$7.36M | 0.29% | 69 |
|
|
2019
Q2 | $15.6M | Buy |
381,948
+141,448
| +59% | +$5.86M | 0.19% | 120 |
|
|
2019
Q1 | $11.2M | Sell |
240,500
-2,258
| -0.9% | -$99.1K | 0.14% | 167 |
|
|
2018
Q4 | $10.6M | Buy |
242,758
+117,758
| +94% | +$5.88M | 0.16% | 147 |
|
|
2018
Q3 | $7.15M | Buy |
125,000
+28,000
| +29% | +$1.38M | 0.1% | 249 |
|
|
2018
Q2 | $4.71M | Buy |
97,000
+37,000
| +62% | +$1.35M | 0.07% | 305 |
|
|
2018
Q1 | $2.35M | Sell |
60,000
-13,000
| -18% | -$553K | 0.04% | 446 |
|
|
2017
Q4 | $3.1M | Sell |
73,000
-45,000
| -38% | -$1.69M | 0.05% | 370 |
|
|
2017
Q3 | $4.4M | Buy |
118,000
+10,000
| +9% | +$347K | 0.08% | 289 |
|
|
2017
Q2 | $3.28M | Sell |
108,000
-74,000
| -41% | -$2.14M | 0.06% | 354 |
|
|
2017
Q1 | $4.82M | Buy |
182,000
+31,000
| +21% | +$817K | 0.09% | 260 |
|
|
2016
Q4 | $3.85M | Buy |
151,000
+57,000
| +61% | +$1.81M | 0.09% | 252 |
|
|
2016
Q3 | $3.4M | Buy |
94,000
+14,000
| +18% | +$464K | 0.08% | 259 |
|
|
2016
Q2 | $2.72M | Sell |
80,000
-35,000
| -30% | -$1.14M | 0.07% | 266 |
|
|
2016
Q1 | $3.02M | Sell |
115,000
-5,000
| -4% | -$145K | 0.08% | 264 |
|
|
2015
Q4 | $5.85M | Buy |
120,000
+19,200
| +19% | +$691K | 0.16% | 152 |
|
|
2015
Q3 | $2.51M | Buy |
100,800
+800
| +0.8% | +$24K | 0.06% | 307 |
|
|
2015
Q2 | $3.16M | Buy |
100,000
+32,000
| +47% | +$1.03M | 0.07% | 304 |
|
|
2015
Q1 | $2.59M | Buy |
68,000
+13,000
| +24% | +$517K | 0.05% | 356 |
|
|
2014
Q4 | $2.14M | Buy |
+55,000
| New | +$1.92M | 0.04% | 350 |
|
Candriam SCA's XLRN Position: Q4 2021 in Review
Candriam SCA sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 462,239 shares — an estimated $79.5M sold.
Candriam SCA first reported a position in XLRN in Q4 2014 and held it in 28 quarters. The position peaked at $79.5M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Candriam SCA reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Candriam SCA sold 462,239 Acceleron Pharma shares in Q4 2021, an estimated $79.5M.
- Candriam SCA first reported a position in Acceleron Pharma in Q4 2014 and held it in 28 quarters.
- Candriam SCA's Acceleron Pharma position peaked at $79.5M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.